High-density lipoprotein, vascular risk, cancer and infection: A case of quantity and quality?

Current Medicinal Chemistry

Volumn 21, Issue 25, 2014, Pages 2917-2926

  Katsiki, N ^a   Athyros, V G ^a   Karagiannis, A ^a   Mikhailidis, D P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cardiovascular disease; High density lipoprotein cholesterol; High density lipoprotein dysfunction; Infection; Vascular risk

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); HUMAN; INFECTION; NEOPLASM; PATHOGENESIS; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; COMMUNICABLE DISEASE; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COMMUNICABLE DISEASES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84906096364     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140303152132     Document Type: Article

References (176)

1. Huxley, R.R.; Barzi, F.; Lam, T.H.; Czernichow, S.; Fang, X.; Welborn, T.; Shaw, J.; Ueshima, H.; Zimmet, P.; Jee, S.H.; Patel, J.V.; Caterson, I.; Perkovic, V.; Woodward, M.; Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation, 2011, 124, 2056-2064.
2. Takagi, H.; Manabe, H.; Kawai, N.; Goto, S.N.; Umemoto, T. Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis. Int. Angiol., 2010, 29, 371-375.
3. Amarenco, P.; Goldstein, L.B.; Callahan, A. 3rd.; Sillesen, H.; Hennerici, M.G.; O'Neill, B.J.; Rudolph, A.E.; Simunovic, L.; Zivin, J.A.; Welch, K.M.; SPARCL Investigators. Baseline blood pressure, low-and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis, 2009, 204, 515-520.
4. Otocka-Kmiecik, A.; Mikhailidis, D.P.; Nicholls, S.J.; Davidson, M.; Rysz, J.; Banach, M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res., 2012, 51, 314-324.
5. Besler, C.; Heinrich, K.; Riwanto, M.; Lüscher, T.F.; Landmesser, U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial- protective effects: a potential novel therapeutic target in cardiovascular disease. Curr. Pharm. Des., 2010, 16, 1480-1493.
6. Florentin, M.; Liberopoulos, E.N.; Wierzbicki, A.S.; Mikhailidis, D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol., 2008, 23, 370-378.
7. Stone, N.J.; Robinson, J.; Lichtenstein, A.H.; Bairey Merz, C.N.; Lloyd-Jones, D.M.; Blum, C.B.; McBride, P.; Eckel, R.H.; Schwartz, J.S.; Goldberg, A.C.; Shero, S.T.; Gordon, D.; Smith, S.C. Jr.; Levy, D.; Watson, K.; Wilson, P.W. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2013, pii: S0735-1097(13)06028-2. [Epub ahead of print]
8. Kostapanos, M.S.; Katsiki, N.; Elisaf, M.S.; Mikhailidis, D.P. Editorial: reducing cardiovascular risk: is low-density lipoproteincholesterol (LDL-C) lowering enough? Curr. Vasc. Pharmacol., 2012, 10, 173-177.
9. Wierzbicki, A.S.; Clarke, R.E.; Viljoen, A.; Mikhailidis, D.P. Triglycerides: a case for treatment? Curr. Opin. Cardiol., 2012, 27, 398-404.
10. Gazi, I.F.; Tsimihodimos, V.; Tselepis, A.D.; Elisaf, M.; Mikhailidis, D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin. Biol. Ther., 2007, 7, 53-72.
11. Athyros, V.G.; Tziomalos, K.; Karagiannis, A.; Mikhailidis, D.P. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc. Med. J., 2011, 5, 24-34.
12. Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Characteristics Other Than the Diagnostic Criteria Associated with Metabolic Syndrome: an Overview. Curr. Vasc. Pharmacol., 2013. [Epub ahead of print]
13. Nikolic, D.; Katsiki, N.; Montalto, G.; Isenovic, E.R.; Mikhailidis, D.P.; Rizzo, M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients, 2013, 5, 928-948.
14. Rizzo, M.; Barylski, M.; Rizvi, A.A.; Montalto, G.; Mikhailidis, D.P.; Banach, M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr. Pharm. Des., 2013, 19, 3858-3868.
15. Gluba, A.; Mikhailidis, D.P.; Lip, G.Y.; Hannam, S.; Rysz, J.; Banach, M. Metabolic syndrome and renal disease. Int. J. Cardiol., 2013, 164, 141-150.
16. Gundogan, K.; Bayram, F.; Gedik, V.; Kaya, A.; Karaman.; Demir, O.; Sabuncu, T.; Kocer, D.; Coskun, R. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch. Med. Sci., 2013, 9, 243-253.
17. Gharipour, M.; Kelishadi, R.; Khosravi, A.; Shirani, S.; Masjedi, M.; Sarrafzadegan, N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. Arch. Med. Sci., 2012, 8, 1009-1017.
18. Mikhailidis, D.P.; Elisaf, M.; Rizzo, M.; Berneis, K.; Griffin, B.; Zambon, A.; Athyros, V.; de Graaf, J.; März, W.; Parhofer, K.G.; Rini, G.B.; Spinas, G.A.; Tomkin, G.H.; Tselepis, A.D.; Wierzbicki, A.S.; Winkler, K.; Florentin, M.; Liberopoulos, E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol., 2011, 9, 531-532.
19. Mikhailidis, D.P.; Elisaf, M.; Rizzo, M.; Berneis, K.; Griffin, B.; Zambon, A.; de Graaf, J.; März, W.; Parhofer, K.G.; Rini, G.B.; Spinas, G.A.; Tomkin, G.H.; Tselepis, A.D.; Wierzbicki, A.S.; Winkler, K.; Florentin, M.; Liberopoulos, E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol., 2011, 9, 533-571.
20. Kolovou, G.D.; Mikhailidis, D.P.; Kovar, J.; Lairon, D.; Nordestgaard, B.G.; Ooi, T.C.; Perez-Martinez, P.; Bilianou, H.; Anagnostopoulou, K.; Panotopoulos, G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr. Vasc. Pharmacol., 2011, 9, 258-270.
21. Kolovou, G.D.; Mikhailidis, D.P.; Nordestgaard, B.G.; Bilianou, H.; Panotopoulos, G. Definition of postprandial lipaemia. Curr. Vasc. Pharmacol., 2011, 9, 292-301.
22. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D.P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des., 2013, 19, 3124-3131.
23. Katsiki, N.; Theocharidou, E.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Ezetimibe therapy for dyslipidemia: an update. Curr. Pharm. Des., 2013, 19, 3107-3114.
24. Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr. Med. Res. Opin., 2011, 27, 693-695.
25. Gazi, I.F.; Daskalopoulou, S.S.; Nair, D.R.; Mikhailidis, D.P. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin., 2007, 23, 2183-2192.
26. Mikhailidis, D.P.; Sibbring, G.C.; Ballantyne, C.M.; Davies, G.M.; Catapano, A.L. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin., 2007, 23, 2009-2026.
27. Mikhailidis, D.P.; Lawson, R.W.; McCormick, A.L.; Sibbring, G.C.; Tershakovec, A.M.; Davies, G.M.; Tunceli, K. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and metaanalysis. Curr. Med. Res. Opin., 2011, 27, 1191-1210.
28. Filippatos, T.D.; Elisaf, M.S. High density lipoprotein and cardiovascular diseases. World J. Cardiol., 2013, 5, 210-214.
29. Vílchez, J.A.; Martínez-Ruiz, A.; Sancho-Rodríguez, N.; Martínez-Hernández, P.; Noguera-Velasco, J.A. The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. Eur. J. Clin. Invest., 2014, 44(1), 103-114.
30. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G.; Wilt, T.J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341, 410-418.
31. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation, 2000, 102, 21-27.
32. Rizos, E.; Mikhailidis, D.P. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int. J. Cardiol., 2002, 82, 199-207; discussion 207-208.
33. Scott, R.; O'Brien, R.; Fulcher, G.; Pardy, C.; D'Emden, M.; Tse, D.; Taskinen, M.R.; Ehnholm, C.; Keech, A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009, 32, 493-498.
34. Ridker, P.M.; Genest, J.; Boekholdt, S.M.; Libby, P.; Gotto, A.M.; Nordestgaard, B.G.; Mora, S.; MacFadyen, J.G.; Glynn, R.J.; Kastelein, J.J.; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, 2010, 376, 333-339.
35. Phan, B.A.; Muñoz, L.; Shadzi, P.; Isquith, D.; Triller, M.; Brown, B.G.; Zhao, X.Q. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDLAtherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study. Am. J. Cardiol., 2013, 111, 352-355.
36. AIM-HIGH Investigators.; Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, 365, 2255-2267.
37. Wang, X.; Dong, Y.; Qi, X.; Huang, C.; Hou, L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and metaanalysis. Stroke, 2013, 44, 1833-1839.
38. Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions. http: //www.mercknews room.com/press-release/research-and-development- news/resultshps2-thrive-study-tredaptive-extended-release-ni (Accessed January 5, 2014).
39. Merck Provides Update on Next Steps for TREDAPTIVE™ (extendedrelease niacin/laropiprant). http://www.mercknewsroom.com/pressrelease/ research-and-development-news/merck-provides-updatenext-steps-tredaptive- extended-rel (Accessed January 5, 2014).
40. Katsiki, N.; Athyros, V.G.; Mikhailidis, D.P. The DEFINE study: a bright future for CETP inhibitors? Expert Opin. Investig. Drugs, 2011, 20, 311-314.
41. Barter, P.J.; Caulfield, M.; Eriksson, M.; Grundy, S.M.; Kastelein, J.J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.C.; Waters, D.D.; Shear, C.L.; Revkin, J.H.; Buhr, K.A.; Fisher, M.R.; Tall, A.R.; Brewer, B.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med., 2007, 357, 2109-2122.
42. Kastelein, J.J.; van Leuven, S.I.; Burgess, L.; Evans, G.W.; Kuivenhoven, J.A.; Barter, P.J.; Revkin, J.H.; Grobbee, D.E.; Riley, W.A.; Shear, C.L.; Duggan, W.T.; Bots, M.L.; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356, 1620-1630.
43. Bots, M.L.; Visseren, F.L.; Evans, G.W.; Riley, W.A.; Revkin, J.H.; Tegeler, C.H.; Shear, C.L.; Duggan, W.T.; Vicari, R.M.; Grobbee, D.E.; Kastelein, J.J.; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet, 2007, 370, 153-160.
44. Nissen, S.E.; Tardif, J.C.; Nicholls, S.J.; Revkin, J.H.; Shear, C.L.; Duggan, W.T.; Ruzyllo, W.; Bachinsky, W.B.; Lasala, G.P.; Tuzcu, E.M.; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med., 2007, 356, 1304-1316.
45. Effects of dalcetrapib on vascular function: results of phase IIb dal-VESSEL study. http://www.escardio.org/about/press/pressreleases/esc11-paris/ Pages/HL1-dal-VESSEL.aspx (Accessed January 5, 2014).
46. Fayad, Z.A.; Mani, V.; Woodward, M.; Kallend, D.; Abt, M.; Burgess, T.; Fuster, V.; Ballantyne, C.M.; Stein, E.A.; Tardif, J.C.; Rudd, J.H.; Farkouh, M.E.; Tawakol, A.; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet, 2011, 378, 1547-1559.
47. Schwartz, G.G.; Olsson, A.G.; Abt, M.; Ballantyne, C.M.; Barter, P.J.; Brumm, J.; Chaitman, B.R.; Holme, I.M.; Kallend, D.; Leiter, L.A.; Leitersdorf, E.; McMurray, J.J.; Mundl, H.; Nicholls, S.J.; Shah, P.K.; Tardif, J.C.; Wright, R.S.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med., 2012, 367, 2089-2099.
48. Media Release: Roche provides update on Phase III study of dalcetrapid. www.roche.com/med-cor-2012-05-07-e.pdf (Accessed January 5, 2014).
49. Bishop, B.M. Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process? Am. J. Ther. 2013. [Epub ahead of print]
50. Cannon, C.P.; Shah, S.; Dansky, H.M.; Davidson, M.; Brinton, E.A.; Gotto, A.M.; Stepanavage, M.; Liu, S.X.; Gibbons, P.; Ashraf, T.B.; Zafarino, J.; Mitchel, Y.; Barter, P. Determining the Efficacy and Tolerability Investigators. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N. Engl. J. Med., 2010, 363, 2406-2415.
51. Nicholls, S.J.; Brewer, H.B.; Kastelein, J.J.; Krueger, K.A.; Wang, M.D.; Shao, M.; Hu, B.; McErlean, E.; Nissen, S.E. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA, 2011, 306, 2099-2109.
52. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. www.clinicaltrials.gov/ct2/show/NCT01252953 (Accessed January 5, 2014).
53. Barter, P.J.; Rye, K.A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res., 2012, 53, 1755-1766.
54. Ridker, P.M.; Pare, G.; Parker, A.N.; Zee, R.Y.L.; Miletich, J.P.; Chasman, D.I. Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women from the Women's Genome Health Study. Circ. Cardiovasc. Genet., 2009, 2, 26-33.
55. Wilson, P.W. CETP genes, metabolic effects, and coronary disease risk. JAMA, 2008, 299, 2795-2796.
56. Thompson, A.; Di Angelantonio, E.; Sarwar, N.; Erqou, S.; Saleheen, D.; Dullaart, R.P.; Keavney, B.; Ye, Z.; Danesh, J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA, 2008, 299, 2777-2788.
57. Chantepie, S.; Bochem, A.E.; Chapman, M.J.; Hovingh, G.K.; Kontush, A. High-densitylipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity. PLoS One, 2012, 7, e49336.
58. Gomaraschi, M.; Baldassarre, D.; Amato, M.; Eligini, S.; Conca, P.; Sirtori, C.R.; Franceschini, G.; Calabresi, L. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I-Milano mutant. Circulation, 2007, 116, 2165-2172.
59. Soumian, S.; Albrecht, C.; Davies, A.H.; Gibbs, R.G. ABCA1 and atherosclerosis. Vasc. Med., 2005, 10, 109-119.
60. Kolovou, G.D.; Mikhailidis, D.P.; Anagnostopoulou, K.K.; Daskalopoulou, S.S.; Cokkinos, D.V. Tangier disease four decades of research: a reflection of the importance of HDL. Curr. Med. Chem., 2006, 13, 771-782.
61. Kolovou, G.; Daskalova, D.; Anagnostopoulou, K.; Hoursalas, I.; Voudris, V.; Mikhailidis, D.P.; Cokkinos, D.V. Postprandial hypertriglyceridaemia in patients with Tangier disease. J. Clin. Pathol., 2003, 56, 937-941.
62. Moennig, G.; Wiebusch, H.; Enbergs, A.; Dorszewski, A.; Kerber, S.; Schulte, H.; Vielhauer, C.; Haverkamp, W.; Assmann, G.; Breithardt, G.; Funke, H. Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography. Atherosclerosis, 2000, 149, 395-401.
63. Dugi, K.A.; Brandauer, K.; Schmidt, N.; Nau, B.; Schneider, J.G.; Mentz, S.; Keiper, T.; Schaefer, J.R.; Meissner, C.; Kather, H.; Bahner, M.L.; Fiehn, W.; Kreuzer, J. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation, 2001, 104, 3057-3062.
64. Athyros, V.G.; Katsiki, N.; Karagiannis, A.; Mikhailidis, D.P. Should raising high-density lipoprotein cholesterol be a matter of debate? J. Cardiovasc. Med. (Hagerstown), 2012, 13, 254-259.
65. Yilmaz, N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch. Med. Sci., 2012, 8, 138-153.
66. Serban, C.; Muntean, D.; Mikhailids, D.P.; Toth, P.P.; Banach, M. Dysfunctional HDL: The Journey from Savior to Slayer. Clin. Lipidol., 2014 (in press); doi: 10.2217/CLP.13.83.
67. Barylski, M.; Toth, P.P.; Nikolic, D.; Banach, M.; Rizzo, M.; Montalto, G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab., 2014. doi: 10.1016/j.beem.2013.11.001 [In press].
68. Toth, P.P.; Barylski, M.; Nikolic, D.; Rizzo, M.; Montalto, G.; Banach, M. Should low high-density lipoprotein cholesterol (HDLC) be treated? Best Pract. Res. Clin. Endocrinol. Metab., 2014, doi: 10.1016/j.beem.2013.1011.1002 [In press].
69. Kontush, A.; Chapman, M.J. Antiatherogenic small, dense HDLguardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 144-153.
70. Yu, R.; Yekta, B.; Vakili, L.; Gharavi, N.; Navab, M.; Marelli, D.; Ardehali, A. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr. Atheroscler. Rep., 2008, 10, 171-176.
71. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Ansell, B.J.; Fogelman, A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat. Clin. Pract. Endocrinol. Metab., 2006, 2, 504-511.
72. Norata, G.D.; Pirillo, A.; Catapano, A.L. Modified HDL: biological and physiopathological consequences. Nutr. Metab. Cardiovasc. Dis., 2006, 16, 371-386.
73. Blache, D.; Gautier, T.; Tietge, U.J.; Lagrost, L. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism. FASEB J., 2012, 26, 927-937.
74. Eren, E.; Yilmaz, N.; Aydin, O. Functionally Defective High-Density Lipoprotein and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis. Cholesterol, 2013, 2013, 792090.
75. Xu, S.; Liu, Z.; Liu, P. HDL cholesterol in cardiovascular diseases: the good, the bad, and the ugly? Int. J. Cardiol., 2013, 168, 3157-3159.
76. Morgantini, C.; Natali, A.; Boldrini, B.; Imaizumi, S.; Navab, M.; Fogelman, A.M.; Ferrannini, E.; Reddy, S.T. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes, 2011, 60, 2617-2623.
77. Ballantyne, C.M.; Miller, M.; Niesor, E.J.; Burgess, T.; Kallend, D.; Stein, E.A. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am. Heart J., 2012, 163, 515-521.
78. Niesor, E.J.; Magg, C.; Ogawa, N.; Okamoto, H.; von der Mark, E.; Matile, H.; Schmid, G.; Clerc, R.G.; Chaput, E.; Blum-Kaelin, D.; Huber, W.; Thoma, R.; Pflieger, P.; Kakutani, M.; Takahashi, D.; Dernick, G.; Maugeais, C. Modulating cholesteryl ester transfer protein activity maintains efficient pre-HDL formation and increases reverse cholesterol transport. J. Lipid Res., 2010, 51, 3443-3454.
79. Otvos, J.D.; Collins, D.; Freedman, D.S.; Shalaurova, I.; Schaefer, E.J.; McNamara, J.R.; Bloomfield, H.E.; Robins, S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 2006, 113, 1556-1563.
80. Asztalos, B.F.; Collins, D.; Cupples, L.A.; Demissie, S.; Horvath, K.V.; Bloomfield, H.E.; Robins, S.J.; Schaefer, E.J. Value of highdensity lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2185-2191.
81. Asztalos, B.F.; Collins, D.; Horvath, K.V.; Bloomfield, H.E.; Robins, S.J.; Schaefer, E.J. Relation of gemfibrozil treatment and highdensity lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism, 2008, 57, 77-83.
82. El Harchaoui, K.; Arsenault, B.J.; Franssen, R.; Després, J.-P.; Hovingh, G.K.; Stroes, E.S.G.; Otvos, J.D.; Wareham, N.J.; Kastelein, J.J.P.; Khaw, K.-T.; Boekholdt, S.M. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk. Ann. Intern. Med., 2009, 150, 84-93.
83. Otvos, J.D. The surprising AIM-HIGH results are not surprising when viewed through a particle lens. J. Clin. Lipidol., 2011, 5, 368-370.
84. Ray, K.K.; Cannon, C.P.; Cairns, R.; Morrow, D.A.; Ridker, P.M.; Braunwald, E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 424-430.
85. Holme, I.; Cater, N.B.; Faergeman, O.; Kastelein, J.J.; Olsson, A.G.; Tikkanen, M.J.; Larsen, M.L.; Lindahl, C.; Pedersen, T.R.; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Ann. Med., 2008, 40, 456-464.
86. van der Steeg, W.A.; Holme, I.; Boekholdt, S.M.; Larsen, M.L.; Lindahl, C.; Stroes, E.S.; Tikkanen, M.J.; Wareham, N.J.; Faergeman, O.; Olsson, A.G.; Pedersen, T.R.; Khaw, K.T.; Kastelein, J.J. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., 2008, 51, 634-642.
87. Tomic, S.; Brkic, S.; Maric, D.; Mikic, A.N. Lipid and protein oxidation in female patients with chronic fatigue syndrome. Arch. Med. Sci., 2012, 8, 886-891.
88. Barylski, M.; Mayszko, J.; Rysz, J.; Myliwiec, M.; Banach, M. Lipids, blood pressure, kidney -what was new in 2011? Arch. Med. Sci., 2011, 7, 1055-1066.
89. Kucera, M.; Oravec, S.; Hirnerova, E.; Huckova, N.; Celecova, Z.; Gaspar, L.; Banach, M. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity: A Pilot Study. Angiology, 2013. [Epub ahead of print]
90. Cruz, P.M.; Mo, H.; McConathy, W.J.; Sabnis, N.; Lacko, A.G. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front. Pharmacol., 2013, 4, 119.
91. Silvente-Poirot, S.; Poirot, M. Cholesterol metabolism and cancer: the good, the bad and the ugly. Curr. Opin. Pharmacol., 2012, 12, 673-676.
92. Singh, P.P.; Singh, S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann. Oncol., 2013, 24, 1721-1730.
93. Singh, S.; Singh, A.G.; Singh, P.P.; Murad, M.H.; Iyer, P.G. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and metaanalysis. Clin. Gastroenterol. Hepatol., 2013, 11, 620-629.
94. Singh, S.; Singh, P.P.; Singh, A.G.; Murad, M.H.; Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology, 2013, 144, 323-332.
95. Sekine, Y.; Demosky, S.J.; Stonik, J.A.; Furuya, Y.; Koike, H.; Suzuki, K.; Remaley, A.T. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol. Cancer Res., 2010, 8, 1284-1294.
96. Vílchez, J.A.; Martínez-Ruiz, A.; Sancho-Rodríguez, N.; Martínez-Hernández, P.; Noguera-Velasco, J.A. The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. Eur. J. Clin. Invest., 2014, 44, 103-114.
97. Pan, B.; Ren, H.; He, Y.; Lv, X.; Ma, Y.; Li, J.; Huang, L.; Yu, B.; Kong, J.; Niu, C.; Zhang, Y.; Sun, W.B.; Zheng, L. HDL of patients with type 2 diabetes mellitus elevates thecapability of promoting breast cancer metastasis. Clin. Cancer Res., 2012, 18, 1246-1256.
98. Thurnher, M.; Nussbaumer, O.; Gruenbacher, G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res., 2012, 18, 3524-3531.
99. Osmak, M. Statins and cancer: current and future prospects. Cancer Lett., 2012, 324, 1-12.
100. Vallianou, N.G.; Kostantinou, A.; Kougias, M.; Kazazis, C. Statins and Cancer. Anticancer Agents Med. Chem., 2013. [Epub ahead of print]
101. Bérard, E.; Bongard, V.; Dallongeville, J.; Arveiler, D.; Ruidavets, J.B.; Ferrières, J. Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population. Curr. Med. Res. Opin., 2011, 27, 1963-1971.
102. Wang, B.; Yuan, Y.; Han, L.; Ye, L.; Shi, X.; Feng, M. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J. Drug Target., 2014, 22, 76-85.
103. Bielecka-Dbrowa, A.; Hannam, S.; Rysz, J.; Banach, M. Malignancy-associated dyslipidemia. Open Cardiovasc. Med. J., 2011, 5, 35-40.
104. Su, F.; Grijalva, V.; Navab, K.; Ganapathy, E.; Meriwether, D.; Imaizumi, S.; Navab, M.; Fogelman, A.M.; Reddy, S.T.; Farias-Eisner, R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol. Cancer Ther., 2012, 11, 1311-1319.
105. Filippatos, T.D.; Liberopoulos, E.N.; Pavlidis, N.; Elisaf, M.S.; Mikhailidis, D.P. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat. Rev., 2009, 35, 175-184.
106. Saylor, P.J.; Smith, M.R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol., 2009, 181, 1998-2008.
107. Strohmaier, S.; Edlinger, M.; Manjer, J.; Stocks, T.; Bjørge, T.; Borena, W.; Häggström, C.; Engeland, A.; Nagel, G.; Almquist, M.; Selmer, R.; Tretli, S.; Concin, H.; Hallmans, G.; Jonsson, H.; Stattin, P.; Ulmer, H. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One, 2013, 8, e54242.
108. Iso, H.; Ikeda, A.; Inoue, M.; Sato, S.; Tsugane, S.; JPHC Study Group. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int. J. Cancer, 2009, 125, 2679-2686.
109. Ahn, J.; Lim, U.; Weinstein, S.J.; Schatzkin, A.; Hayes, R.B.; Virtamo, J.; Albanes, D. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 2814-2821.
110. Mondul, A.M.; Weinstein, S.J.; Virtamo, J.; Albanes, D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control, 2011, 22, 1545-1552.
111. Platz, E.A.; Till, C.; Goodman, P.J.; Parnes, H.L.; Figg, W.D.; Albanes, D.; Neuhouser, M.L.; Klein, E.A.; Thompson, I.M. Jr.; Kristal, A.R. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 2807-2813.
112. Jafri, H.; Alsheikh-Ali, A.A.; Karas, R.H. Baseline and ontreatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J. Am. Coll. Cardiol., 2010, 55, 2846-2854.
113. van Duijnhoven, F.J.; Bueno-De-Mesquita, H.B.; Calligaro, M.; Jenab, M.; Pischon, T.; Jansen, E.H.; Frohlich, J.; Ayyobi, A.; Overvad, K.; Toft-Petersen, A.P.; Tjønneland, A.; Hansen, L.; Boutron-Ruault, M.C.; Clavel-Chapelon, F.; Cottet, V.; Palli, D.; Tagliabue, G.; Panico, S.; Tumino, R.; Vineis, P.; Kaaks, R.; Teucher, B.; Boeing, H.; Drogan, D.; Trichopoulou, A.; Lagiou, P.; Dilis, V.; Peeters, P.H.; Siersema, P.D.; Rodríguez, L.; González, C.A.; Molina-Montes, E.; Dorronsoro, M.; Tormo, M.J.; Barricarte, A.; Palmqvist, R.; Hallmans, G.; Khaw, K.T.; Tsilidis, K.K.; Crowe, F.L.; Chajes, V.; Fedirko, V.; Rinaldi, S.; Norat, T.; Riboli, E. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut, 2011, 60, 1094-1102.
114. Kotani, K.; Sekine, Y.; Ishikawa, S.; Ikpot, I.Z.; Suzuki, K.; Remaley, A.T. High-density lipoprotein and prostate cancer: an overview. J. Epidemiol., 2013, 23, 313-319.
115. Jacobs, E.J.; Stevens, V.L.; Newton, C.C.; Gapstur, S.M. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control, 2012, 23, 1289-1296.
116. Kim, Y.; Park, S.K.; Han, W.; Kim, D.H.; Hong, Y.C.; Ha, E.H.; Ahn, S.H.; Noh, D.Y.; Kang, D.; Yoo, K.Y. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 508-515.
117. Kucharska-Newton, A.M.; Rosamond, W.D.; Mink, P.J.; Alberg, A.J.; Shahar, E.; Folsom, A.R. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann. Epidemiol., 2008, 18, 671-677.
118. Fang, D.H.; Fan, C.H.; Ji, Q.; Qi, B.X.; Li, J.; Wang, L. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol. Biol. Rep., 2012, 39, 6801-6809.
119. Lindemann, K.; Vatten, L.J.; Ellstrøm-Engh, M.; Eskild, A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. Int. J. Cancer, 2009, 124, 2938-2941.
120. Seth, D.; Garmo, H.; Wigertz, A.; Holmberg, L.; Hammar, N.; Jungner, I.; Lambe, M.; Walldius, G.; Van Hemelrijck, M. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int. J. Mol. Epidemiol. Genet., 2012, 3, 122-133.
121. Singh, I.M.; Shishehbor, M.H.; Ansell, B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA, 2007, 298, 786-798.
122. Sirtori, C.R. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert Opin. Investig. Drugs, 2011, 20, 1543-1554.
123. Kirkland, J.B. Niacin and carcinogenesis. Nutr. Cancer, 2003, 46, 110-118.
124. Kirkland, J.B. Niacin status and treatment-related leukemogenesis. Mol. Cancer Ther., 2009, 8, 725-732.
125. Maitra, A.; Shanker, J.; Dash, D.; Arvind, P.; Kakkar, V.V. Understanding the expression of Toll-like receptors in Asian Indians predisposed to coronary artery disease. Arch. Med. Sci., 2011, 7, 781-787.
126. Gluba, A.; Banach, M.; Hannam, S.; Mikhailidis, D.P.; Sakowicz, A.; Rysz, J. The role of Toll-like receptors in renal diseases. Nat. Rev. Nephrol., 2010, 6, 224-235.
127. Zhu, X.; Parks, J.S. New roles of HDL in inflammation and hematopoiesis. Annu. Rev. Nutr., 2012, 32, 161-182.
128. Murch, O.; Collin, M.; Hinds, C.J.; Thiemermann, C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med., 2007, 33, 13-24.
129. Chalubinski, M.; Wojdan, K.; Dorantowicz, R.; Jackowska, P.; Gorzelak, P.; Broncel, M. Comprehensive insight into immune regulatory mechanisms and vascular walldeterminants of atherogenesis -emerging perspectives of immunomodulation. Arch. Med. Sci., 2013, 9, 159-165.
130. Khazaei, M.; Nematbakhsh, M. Effect of experimentally induced metabolic acidosis on aortic endothelial permeability and serum nitric oxide concentration in normal and high-cholesterol fed rabbits. Arch. Med. Sci., 2012, 8, 719-723.
131. Han, R. Plasma lipoproteins are important components of the immune system. Microbiol. Immunol., 2010, 54, 246-253.
132. Haas, M.J.; Mooradian, A.D. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab. Res. Rev., 2010, 26, 90-99.
133. Khovidhunkit, W.; Kim, M.S.; Memon, R.A.; Shigenaga, J.K.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res., 2004, 45, 1169-1196.
134. Vuilleumier, N.; Dayer, J.M.; von Eckardstein, A.; Roux-Lombard, P. Pro-or anti-inflammatory role of apolipoprotein A-1 in highdensity lipoproteins? Swiss Med. Wkly., 2013, 143, w13781.
135. Gillard, B.K.; Raya, J.L.; Ruiz-Esponda, R.; Iyer, D.; Coraza, I.; Balasubramanyam, A.; Pownall, H.J. Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function. Arterioscler. Thromb. Vasc. Biol., 2013, 33, 1714-1721.
136. Jia, E.Z.; Zhao, F.J.; Hao, B.; Zhu, T.B.; Wang, L.S.; Chen, B.; Cao, K.J.; Huang, J.; Ma, W.Z.; Yang, Z.J.; Zhang, G. Helicobacter pylori infection is associated with decreased serum levels of high density lipoprotein, but not with the severity of coronary atherosclerosis. Lipids Health Dis., 2009, 8, 59.
137. Negro, F.; Sanyal, A.J. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int., 2009, 29, 26-37.
138. Vekic, J.; Zeljkovic, A.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V.; Spasic, S.; Videnovic-Ivanov, J.; Ivanisevic, J.; Vucinic-Mihailovic, V.; Gojkovic, T. Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis. Arch. Pathol. Lab. Med., 2013, 137, 1780-1787.
139. Katsiki, N.; Anagnostis, P.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Psoriasis and vascular risk: an update. Curr. Pharmacol. Des., 2013. [In press].
140. Norata, G.D.; Pirillo, A.; Ammirati, E.; Catapano, A.L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis, 2012, 220, 11-21.
141. Balta, I.; Balta, S.; Demirkol, S.; Mikhailidis, D.P.; Celik, T.; Akhan, M.; Kurt, O.; Kurt, Y.G.; Aydin, I.; Kilic, S. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br. J. Dermatol., 2013, 169, 1066-1070.
142. Gasparyan, A.Y.; Stavropoulos-Kalinoglou, A.; Mikhailidis, D.P.; Toms, T.E.; Douglas, K.M.; Kitas, G.D. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr. Vasc. Pharmacol., 2010, 8, 437-449.
143. Papadakis, J.A.; Sidiropoulos, P.I.; Karvounaris, S.A.; Vrentzos, G.E.; Spanakis, E.K.; Ganotakis, E.S.; Kritikos, H.D.; Mikhailidis, D.P.; Boumpas, D.T. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin. Exp. Rheumatol., 2009, 27, 292-298.
144. Paraskevas, K.I.; Katsiki, N.; Tzovaras, A.A.; Koupidis, S.A.; Mikhailidis, D.P. Peripheral arterial disease and HIV-positive patients. Angiology, 2011, 62, 7-9.
145. Papa, A.; Scaldaferri, F.; Danese, S.; Guglielmo, S.; Roberto, I.; Bonizzi, M.; Mocci, G.; Felice, C.; Ricci, C.; Andrisani, G.; Fedeli, G.; Gasbarrini, G.; Gasbarrini, A. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig. Dis., 2008, 26, 149-155.
146. Fedele, F.; Bruno, N.; Mancone, M. Cardiovascular risk factors and HIV disease. AIDS Rev., 2011, 13, 119-129.
147. Christiansen, C.F. Risk of vascular disease in patients with multiple sclerosis: a review. Neurol. Res., 2012, 34, 746-753.
148. Filippatos, T.D.; Derdemezis, C.S.; Voulgari, P.V.; Tsimihodimos, V.; Elisaf, M.S.; Tselepis, A.D.; Drosos, A.A. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand. J. Rheumatol., 2013, 42, 169-175.
149. van Vollenhoven, R.F.; Fleischmann, R.; Cohen, S.; Lee, E.B.; García Meijide, J.A.; Wagner, S.; Forejtova, S.; Zwillich, S.H.; Gruben, D.; Koncz, T.; Wallenstein, G.V.; Krishnaswami, S.; Bradley, J.D.; Wilkinson, B.; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med., 2012, 367, 508-519.
150. Souza, S.J.; Luzia, L.A.; Santos, S.S.; Rondó, P.H. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev. Assoc. Med. Bras., 2013, 59, 186-198.
151. Rodríguez-Sanz, A.; Fuentes, B.; Martínez-Sánchez, P.; Prefasi, D.; Martínez-Martínez, M.; Correas, E.; Díez-Tejedor, E. High-density lipoprotein: a novel marker for risk of in-hospital infection in acute ischemic stroke patients? Cerebrovasc. Dis., 2013, 35, 291-297.
152. Cantürk, Z.; Cantürk, N.Z.; Cetinarslan, B.; Utkan, N.Z.; Tarkun, I. Nosocomial infections and obesity in surgical patients. Obes. Res., 2003, 11, 769-775.
153. Delgado-Rodríguez, M.; Medina-Cuadros, M.; Martínez- Gallego, G.; Sillero-Arenas, M. Total cholesterol, HDL-cholesterol, and risk of nosocomial infection: a prospective study in surgical patients. Infect. Control Hosp. Epidemiol., 1997, 18, 9-18.
154. Visser, B.J.; Wieten, R.W.; Nagel, I.M.; Grobusch, M.P. Serum lipids and lipoproteins in malaria -a systematic review and metaanalysis. Malar. J., 2013, 12, 442.
155. Wang, H.; Peng, D.Q. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis., 2011, 10, 176.
156. Athyros, V.G.; Katsiki, N.; Tziomalos, K.; Gossios, T.D.; Theocharidou, E.; Gkaliagkousi, E.; Anagnostis, P.; Pagourelias, E.D.; Karagiannis, A.; Mikhailidis, D.P.; GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch. Med. Sci., 2013, 9, 418-426
157. Barylski, M.; Kowalczyk, E.; Banach, M.; Ciecwierz, J.; Pawlicki, L.; Kowalski, J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology, 2009, 60, 87-92.
158. Lagos, K.G.; Filippatos, T.D.; Tsimihodimos, V.; Gazi, I.F.; Rizos, C.; Tselepis, A.D.; Mikhailidis, D.P.; Elisaf, M.S. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids, 2009, 44, 9-16.
159. van de Woestijne, A.P.; Monajemi, H.; Kalkhoven, E.; Visseren, F.L. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes. Rev., 2011, 12, 829-840.
160. Slagter, S.N.; van Vliet-Ostaptchouk, J.V.; Vonk, J.M.; Boezen, H.M.; Dullaart, R.P.; Kobold, A.C.; Feskens, E.J.; van Beek, A.P.; van der Klauw, M.M.; Wolffenbuttel, B.H. Associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med., 2013, 11, 195.
161. Lee, P.N.; Forey, B.A.; Coombs, K.J. Systematic review with metaanalysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer, 2012, 12, 385.
162. Malek, M.; Aghili, R.; Emami, Z.; Khamseh, M.E. Risk of Cancer in Diabetes: The Effect of Metformin. ISRN Endocrinol., 2013, 2013, 636927.
163. Duaso, M.; Duncan, D. Health impact of smoking and smoking cessation strategies: current evidence. Br. J. Community Nurs., 2012, 17, 356-363.
164. Esposito, K.; Chiodini, P.; Colao, A.; Lenzi, A.; Giugliano, D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care, 2012, 35, 2402-2411.
165. Sundaram, S.; Johnson, A.R.; Makowski, L. Obesity, metabolism and the microenvironment: Links to cancer. J. Carcinog., 2013, 12, 19.
166. Galleri, L.; Sebastiani, G.; Vendrame, F.; Grieco, F.A.; Spagnuolo, I.; Dotta, F. Viral infections and diabetes. Adv. Exp. Med. Biol., 2012, 771, 252-271.
167. Gonçalves, R.B.; Coletta, R.D.; Silvério, K.G.; Benevides, L.; Casati, M.Z.; da Silva, J.S.; Nociti, F.H. Jr. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm. Res., 2011, 60, 409-424.
168. Hegde, V.; Dhurandhar, N.V. Microbes and obesity-interrelationship between infection, adipose tissue and the immune system. Clin. Microbiol. Infect., 2013,19, 314-320.
169. Kalra, S.; Agrawal, N. Diabetes and HIV: current understanding and future perspectives. Curr. Diab. Rep., 2013, 13, 419-427.
170. Koethe, J.R.; Hulgan, T.; Niswender, K. Adipose tissue and immune function: a review of evidence relevant to HIV infection. J. Infect. Dis., 2013, 208, 1194-1201.
171. Naing, C.; Mak, J.W.; Wai, N.; Maung, M. Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection? Curr. Diab. Rep., 2013, 13, 428-434.
172. Negro, F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut, 2010, 59, 1279-1287.
173. Tamashiro, K.L.; Sakai, R.R.; Shively, C.A.; Karatsoreos, I.N.; Reagan, L.P. Chronic stress, metabolism, and metabolic syndrome. Stress, 2011, 14, 468-474.
174. Kim, K.I.; Oh, S.W.; Ahn, S.; Heo, N.J.; Kim, S.; Chin, H.J.; Na, K.Y.; Chae, D.W.; Kim, C.H.; Kim, S. CRP level and HDL cholesterol concentration jointly predict mortality in a Korean population. Am. J. Med., 2012, 125, 787-795.
175. Melvin, J.C.; Holmberg, L.; Rohrmann, S.; Loda, M.; Van Hemelrijck, M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J. Cancer Epidemiol., 2013, 2013, 823849.
176. Morton, J.; Ng, M.K.; Chalmers, J.; Woodward, M.; Mancia, G.; Poulter, N.R.; Marre, M.; Cooper, M.E.; Zoungas, S.; ADVANCE collaborative group. The association of high-density lipoprotein cholesterol with cancer incidence in type ii diabetes: a case of reverse causality? Cancer Epidemiol. Biomarkers Prev., 2013, 22, 1628-1633.